DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Yao J, Bergsland E, Aggarwal R, Aparicio A, et al. Oncologist 2022;27:940-951.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yao J, Bergsland E, Aggarwal R, Aparicio A, et al. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 2022;27:940-951.
PMID: 35983951